[
  {
    "ts": null,
    "headline": "Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025",
    "summary": "SAN FRANCISCO, October 27, 2025--Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement",
    "url": "https://finnhub.io/api/news?id=8befe1beb95a5055b43de9d3fad12ebb8ac7ddb570085a7217dba69a88281e88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761591960,
      "headline": "Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025",
      "id": 137235740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, October 27, 2025--Edwards Lifesciences (NYSE: EW) today announced data demonstrating successful patient outcomes supporting its portfolio of mitral and tricuspid therapies. One-year data from the ENCIRCLE single-arm pivotal trial achieved all primary and secondary endpoints for safety and effectiveness, with outcomes simultaneously published in The Lancet. Thirty-day data from the EVOQUE system STS/ACC TVT Registry, the largest real-world transcatheter tricuspid valve replacement",
      "url": "https://finnhub.io/api/news?id=8befe1beb95a5055b43de9d3fad12ebb8ac7ddb570085a7217dba69a88281e88"
    }
  },
  {
    "ts": null,
    "headline": "Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025",
    "summary": "SAN FRANCISCO, October 27, 2025--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards’ leadership in setting the standard for lasting valve performance and excellent patien",
    "url": "https://finnhub.io/api/news?id=ab6f89b1056f9f83331d57146575247f99a513653812818acf4780faf51cc5b6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761589320,
      "headline": "Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025",
      "id": 137231159,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, October 27, 2025--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical outcomes at one year, also demonstrate excellent long-term valve performance and durability. Separately, 10-year results from PARTNER 2 intermediate risk studies reinforce Edwards’ leadership in setting the standard for lasting valve performance and excellent patien",
      "url": "https://finnhub.io/api/news?id=ab6f89b1056f9f83331d57146575247f99a513653812818acf4780faf51cc5b6"
    }
  },
  {
    "ts": null,
    "headline": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
    "summary": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=7a6d82a8abc2b9ba76c6fe09110cc8010af7480d7e122f61569779fded078f1e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761582600,
      "headline": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
      "id": 137257370,
      "image": "",
      "related": "EW",
      "source": "MarketWatch",
      "summary": "Edwards Lifesciences Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=7a6d82a8abc2b9ba76c6fe09110cc8010af7480d7e122f61569779fded078f1e"
    }
  },
  {
    "ts": null,
    "headline": "Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "summary": "Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=8f6c9881b1ef19a2ace94ec3bc1b561cdbf6b45d9172390f7405044b99f63e9f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761573616,
      "headline": "Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "id": 137229003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=8f6c9881b1ef19a2ace94ec3bc1b561cdbf6b45d9172390f7405044b99f63e9f"
    }
  },
  {
    "ts": null,
    "headline": "Cardiovascular Repair & Reconstruction Devices - Global Market Forecast (2025-2032) Featuring Profiles of Medtronic, Edwards Lifesciences, Abbott Labs, Boston Scientific, Terumo and More",
    "summary": "The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The \"Card",
    "url": "https://finnhub.io/api/news?id=b58be3d3795a99203330d36b0797f29aec86fe493585c681251eab4e7c1eb01f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761568200,
      "headline": "Cardiovascular Repair & Reconstruction Devices - Global Market Forecast (2025-2032) Featuring Profiles of Medtronic, Edwards Lifesciences, Abbott Labs, Boston Scientific, Terumo and More",
      "id": 137228658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "EW",
      "source": "Yahoo",
      "summary": "The cardiovascular repair market is fueled by an aging population, technological advancements, and the rise in comorbidities. Opportunities lie in innovative, minimally invasive devices, value-based contracting, and regional market dynamics. Emphasizing personalized, data-driven solutions and supply chain resilience is crucial for growth. Cardiovascular Repair & Reconstruction Devices Market Cardiovascular Repair & Reconstruction Devices Market Dublin, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The \"Card",
      "url": "https://finnhub.io/api/news?id=b58be3d3795a99203330d36b0797f29aec86fe493585c681251eab4e7c1eb01f"
    }
  }
]